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Background: This randomized, placebo-controlled, double-blind pilot study evaluated the 
impact of repetitive transcranial magnetic stimulation (rTMS) on clinical, cognitive, and social 
performance in women suffering with postpartum depression.
Methods: Fourteen patients were randomized to receive 20 sessions of sham rTMS or 
active 5 Hz rTMS over the left dorsolateral prefrontal cortex. Psychiatric clinical scales and a 
neuropsychological battery were applied at baseline (pretreatment), week 4 (end of treatment), 
and week 6 (follow-up, posttreatment week 2).
Results: The active rTMS group showed significant improvement 2 weeks after the end of 
rTMS treatment (week 6) in Hamilton Depression Rating Scale (P = 0.020), Global Assessment 
Scale (P = 0.037), Clinical Global Impression (P = 0.047), and Social Adjustment Scale-Self 
Report-Work at Home (P = 0.020).
Conclusion: This study suggests that rTMS has the potential to improve the clinical condition 
in postpartum depression, while producing marginal gains in social and cognitive function.
Keywords: transcranial magnetic stimulation, postpartum depression, clinical performance, 
cognitive performance, social performance
Introduction
Postpartum depression (PPD) is a depressive condition that can start within the first 
4 weeks after delivery and shows the same nosological dimensions as major depression, 
eg, low mood, increased vulnerability to stress, social impairment, and cognitive 
deficits of relative importance, in association with an increased rate of dysphoric 
symptoms.1
PPD often represents a type of major depressive episode. Currently, it is believed 
that major depression postpartum affects around 7% of all women, whereas the inclu-
sion of minor depression raises this rate to 19%.2 However, these numbers may be 
underestimated; the prevalence of the disorder is up to 60% in certain developing 
countries, which seldom receive the same attention as developed countries based on 
international epidemiological studies.3
Leaving aside the risk factors shared with major depression (eg, carrying one or 
more copies of the s allele of 5-HTTLPR),4 as well as previous depressive episodes, 
vulnerability to PPD has mostly been associated with unintended pregnancy, domestic 
violence, single status, and poor-quality relationships.5
This disorder not only represents an ominous condition for the mother (to a lesser 
extent it may also affect the father),6 but it can also have deleterious effects on the 
child.7 Studies have suggested that PPD can affect birth outcomes and neonatal health, 
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lead to future decreases in the infant’s self-esteem, impair 
the establishment of social boundaries, decrease academic 
achievement, and increase twofold the risk of depression 
during childhood and adolescence.8,9
There are several hypotheses about the pathway that leads 
to the transmission of such effects. One perspective that has 
received much attention is that it involves both innate vul-
nerability and inappropriate learning, generated by exposure 
to maladaptive cognition and depressive affect. This inap-
propriate cognition and affect is often tied to the inability to 
cope with the mental and practical pressures represented by 
readjustment of family organization, as revealed by a recent 
study which found that multiple births dramatically increase 
(45%) the chances of developing PPD.10 This perspective 
underscores the importance of enhancing the social and 
cognitive properties of the minds of patients suffering from 
PPD, in order to promote quality of life for the family and 
mitigate the impact on the child.11
PPD continues to be underdiagnosed and undertreated, 
despite increased awareness. Several risk factors have been 
identified, including anxiety or depression during pregnancy, 
a history of depression, and increased life stressors. Treatment 
for depression has been found to be mandatory during preg-
nancy and while breastfeeding for the quality of life of the 
family. However, the risks and benefits of specific treatment 
strategies must be carefully evaluated and balanced, in light 
of the particular features of the period.12 This perspective 
speaks directly to the cost/benefits of psychiatric medications 
in the treatment of PPD.13
These cost/benefits must take into consideration the 
potential risks to the newborn, which remain under debate 
(“… although rates of adverse events are low, serum level 
of antidepressants in the infant can vary widely, and the 
long-term outcome of infants exposed during breastfeeding 
is unknown”).14 It is also worth considering that the time 
window of lactation is narrow, whereas antidepressants 
usually take around 3–8 weeks to produce any phenom-
enological effect; finally, records provided to the US Food 
and Drug Administration show that even the most modern 
antidepressants show unimpressive clinical efficacy in certain 
depressive conditions.15 This situation highlights the need 
for methods to replace medication, while considering the 
perspective that psychotherapy alone is less effective than 
when combined with pharmacological treatment.16
The traditional option is electroconvulsive therapy, which 
is not only viewed as being aggressive, mostly because it leads 
to transient (and maybe long-term) cognitive impairment, 
but can also turn out to be particularly counterproductive in 
this context.17 Thus, in this sense, a potentially interesting 
alternative is represented by repetitive transcranial magnetic 
stimulation (rTMS), which yields immediate effects of a 
similar intensity to that of electroconvulsive therapy,18 but 
is safe (low risk of seizures and cognitive impairment) and 
much less aggressive.19 The technique is based on induction 
of focal electrical fields in the brain through magnetic pulses 
that are generated by an insulated metal coil placed over 
the scalp.20,21 These electrical fields augment the efficacy 
of neurotransmission, increase metabolic rates in related 
neuronal tissues, and induce expression of genes that extend 
the duration of near-immediate effects.22
Over the last decade, an increasing number of studies 
have investigated the potential of rTMS as an aid in the treat-
ment of depression; from 2001 to 2011, 12 meta-analyses of 
the antidepressant efficacy of rTMS were indexed in PubMed. 
The first one was published by Holtzheimer et al,23 while the 
most recent one was published by Schutter, who concluded 
that active rTMS has an effect size of 0.63.24
According to another recent uncontrolled study 
on the efficacy of rTMS in the treatment of PPD, nine 
antidepressant-free women with PPD were given 20 sessions 
of rTMS treatment over 4 weeks (10 Hz, 120% motor 
threshold, left dorsolateral prefrontal cortex). Duration 
of effect was assessed at 30 days, and at 3 months and 
6 months after treatment. Multiple characteristics were 
assessed at baseline and throughout treatment. Assessments 
included the Hamilton Rating Scale for Depression-24 items, 
Edinburgh Postnatal Depression Scale (EPDS), Inventory 
of Depressive Symptomatology-Self-Report, and Clinical 
Global Impression-Severity scores to compare performances 
at four time points (baseline, end of week 2, end of week 4, 
and 180-day follow-up). Significant effects were noticed after 
only 2 weeks of treatment, with eight out of nine patients 
remitting from depression after 4 weeks, and seven out of 
these eight patients remaining in remission after 180 days. 
Further randomized, sham-controlled studies need to be 
completed.25 Controlled studies with the same objective 
and scope have not been published so far, nor have studies 
addressing changes in cognitive and social performances.
The importance of appropriate cognitive and social strate-
gies for coping with the challenge of parenting is evident, and 
it is interesting to note that a recent meta-analysis suggested 
that rTMS increases cognitive function in individuals suffer-
ing from major depression.26 This effect probably relates to 
the fact that rTMS selectively modulates gamma-band oscil-
lations (30–50 Hz) in the prefrontal cortex (measured using 
electroencephalography) through stimulation of fast-spiking 
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GABAergic neurons that synchronize the pyramidal cells 
of the neural networks needed for proper performance in 
different types of working memory tasks.27 In this sense, it 
has been argued that rTMS can produce cognitive enhance-
ment in normal working memory tasks, in association with 
increases in neural efficiency.28
In relation to the potential positive consequences of rTMS 
on social performance and its association with clinical and 
cognitive performance, relevant data are notably scarce. As 
revealed by our thorough review of the literature indexed in 
PubMed and Institute of Scientific Information, there is not 
a single experimental study addressing these questions to 
date. This is somewhat surprising, considering that several 
etiological models of depression are based upon the assump-
tion that the disorder impacts social abilities and cognitive 
functions29 and that, at a deep evolutionary level, it may have 
evolved as a cry for help, which may be particularly important 
in PPD.30 In this sense, we believe that an evaluation of social 
performance in treatment of PPD with rTMS is important 
and that these data should be considered in light of clinical 
and cognitive results.
Considering the potentially positive cost/benefits of rTMS 
in PPD, the current double-blind, randomized, controlled 
pilot study was primarily designed to evaluate the efficacy 
of active rTMS (in comparison with sham rTMS), with a 
focus on clinical conditions, cognitive abilities, and social 
performance.
Materials and methods
Sample
The study sample consisted of 14 women of mean age 28.15 
(range 18–36) years who had given birth 1–6 months (mean 
age of newborns 3.81 months) before the beginning of this 
clinical trial and who were diagnosed with major depres-
sion with a puerperal onset, according to the criteria of the 
DSM-IV-TR (Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision) as well as through 
a structured clinical interview.31 None of the participants were 
receiving any pharmacological treatment other than clon-
azepam 1 mg/day for insomnia and/or physical symptoms. 
Specifically, there were three patients allocated to the active 
group, whose insomnia and physical symptoms were more 
intense than average, eg, heart palpitations and headaches, 
therefore requiring benzodiazepines.
Measures and procedures
The eligibility criteria included baseline scores of at least 
14 points on the 17 item-Hamilton Depression Rating 
Scale (HDRS/17)32 and at least 13 points on the EPDS.33 
Exclusion criteria included ferromagnetic metallic implants, 
pacemakers, previous neurosurgery, history of seizures, 
major head trauma, alcoholism, drug addiction, any psychiat-
ric or neurological disorder other than depression and anxiety, 
psychotic depression, and suicidal propensity.
The study was conducted in compliance with the 
Declaration of Helsinki and its amendments,34 and the norms 
of the local institutional review board. The experimental 
protocol (0588/07) was approved by the local research ethics 
committee and all patients provided their written informed 
consent. This trial is registered at http://www.ClinicalTrials.
gov/ (NCT01452321).
The participants were randomized to one of two 
groups, ie, for active rTMS (eight participants, mean 
age 29.63 ± 6.37 years) or for sham stimulation (six partici-
pants, mean age 26.67 ± 7.15 years). Unrestricted randomiza-
tion was performed using a computerized random-number 
generator (random.org) according to CONSORT guidelines. 
Subjects assigned to the active rTMS group received repeti-
tive stimulation at 120% of the motor threshold for 4 weeks 
(5 days/week). Each weekday, the subjects received 5 Hz 
stimulations as follows: 25 trains (1250 pulses) per day, each 
train lasting 10 seconds, with 20-second intervals between 
trains.35 Stimulation was generated over the left dorsolateral 
prefrontal cortex, which was assumed to be exactly 5 cm 
rostral to the point of optimal stimulation for the right abduc-
tor pollicis brevis muscle in the left parasagittal plane.36 We 
used an eight-shape coil perpendicular to an imaginary line 
extending from the point of stimulation to the nose of the 
participant; sham stimulation followed the same protocol, but 
using a placebo coil. The stimulation was performed using 
a high-speed magnetic stimulator (MagVenture; Medtronic, 
Minneapolis, MN). The motor threshold of the right abductor 
pollicis brevis (a thumb muscle) was determined, as described 
elsewhere.36 Patients in the placebo group were provided 
with the option to receive active treatment immediately after 
completion of the blind phase.
Evaluation of clinical, neurocognitive,  
and social performance
A board-certified neuropsychologist, who was blinded 
to the findings of the other raters and to the study group 
assignment (did not had access to the laboratory where 
rTMS treatment was administered or to records containing 
patient data and study procedures), conducted the clinical, 
neurocognitive, and social performance evaluation on the 
day before initiation of treatment (baseline), after 4 weeks 
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(week 4, end of treatment), and at follow-up (week 6, 
2 weeks after treatment). The two main outcome measures 
were changes in HDRS/1732 and EPDS33 scores. A positive 
response to treatment was defined as a reduction of at least 
30% in HDRS/17 and EPDS scores.
Clinical evaluation
The clinical evaluation included the HDRS/17 and the 
EPDS; the 14 item-Hamilton Anxiety Scale (HARS/14)37; 
the Clinical Global Impression (CGI, 1-Global Impression 
of Severity, 2-Global Impression of Change and 3-Quality 
of Life37); the Global Assessment Scale37; and the Medical 
Outcomes Study 36-item Short-Form Health Survey (SF-36)-
Quality of Life (in order to quantify health-related quality 
of life, comprising eight fields: functional capacity, physical 
aspects, pain, general health, vitality, social aspects, emo-
tional aspects, and mental health38).
Neurocognitive assessment
The neurocognitive battery was comprised of the following 
tests: Executive function – Trail Making Test (parts A and B); 
Wisconsin Card Sorting Test (completed number of catego-
ries, total errors, and perseverative errors); Controlled Oral 
Word Association Test (phonemic category: letters F/A/S and 
semantic category: animals); Victoria Stroop Test (colors, 
color-word, and color-word interference). Learning through 
immediate memory ability – Rey Auditory Verbal Learning 
Test (immediate recall: better performance in trials list A 
and total performance of 5-trials list A; retention: trial A6 
and delayed recall: trial A7).39,40 Other specific cognitive 
functions – WAIS-III [adapted for use in Brazil] - subtests: 
similarities (abstract verbal reasoning), picture completion 
(ability to perceive visual details quickly), digit span forward, 
backward and total (attention, con centration, mental control, 
working memory) and coding (visual-motor coordination, 
motor and mental speed, visual working memory).41
This neurocognitive battery was defined based on two 
perspectives: the importance of each of these tests to the 
neuropsychological evaluation of subjects suffering with 
affective disorders, especially depression,26 and the skills that 
are critical to motherhood, particularly in light of the neces-
sity to cope with the stress that stems from the psychological 
conditions associated with the postpartum period.42
Social performance
In order to evaluate changes in social performance, we used 
the Social Adjustment Scale-Self Report, adapted for use 
in Brazil.43 This scale comprises six independent behavioral 
subscales (work at home [house activities], social/leisure 
[social life and leisure activities], extended family–primary 
relationship [relationships with family members], parental 
[relationship with spouse or partner], unit–child [relationship 
with children], and financial situation [current economic 
condition], which generate an index of overall social 
performance). The Social Adjustment Scale-Self Report is a 
self-report scale that was administered while a certified evalu-
ator was observing but not interacting with the subjects.
Statistical analysis
Demographic and diagnostic data and baseline scores on 
rating scales were compared between groups using the 
Student’s t-test, non-parametric Wilcoxon–Mann–Whitney 
test, or Fisher’s exact test, as applicable. Fisher’s exact 
test was used to compare the two groups in terms of the 
proportion of patients in each group. For all other outcome 
measures, as well as for the neuropsychological battery test 
scores, the effects of group, time, and group × time interac-
tion (longitudinal comparison between the groups) were 
determined using repeated-measures analysis of variance 
(ANOVA). In order to evaluate treatment efficacy, mean and 
the standard deviation for each variable are reported in three 
different moments (baseline, week 4, and week 6). Interaction 
effects tests are also reported (baseline versus week 4, week 
4 versus week 6, and baseline versus week 6). The residual 
normality assumption of the model was confirmed by the 
Kolmogorov–Smirnov test. We performed Bonferroni cor-
rection, as well as a post hoc correction for multiple testing, 
using the false discovery rate, which is generally considered 
to be most appropriate in this context.44
All tests were two-tailed, and the level of significance was 
set at P , 0.05. Statistical analysis was performed using the 
Statistical Package for Social Sciences version 19.0 for Win-
dows (SPSS IBM Corporation, Armonk, NY). Only patients 
who completed the study were included in the analysis.
Results
Demographic and clinical profile
Of the 14 patients included in the study, all completed the 
study (all breastfed their babies at least until week 6) and 
were included in analysis. At baseline, both groups were 
comparable in terms of demographic and psychopathological 
variables (active rTMS, n = 8; sham rTMS, n = 6).
The ABIPEME (Association of Marketing Research 
Firms in Brazil) classification system subdivides the Brazilian 
population into categories according to socioeconomic 
status. It includes items addressing material possessions and 
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educational level of the family members. The socioeconomic 
classification is divided in five classes, ie, A, B, C, D, and E, in 
accordance with the scores achieved for material possessions 
and educational level.
In relation to diagnosis and history of disease, three patients 
in the active rTMS group and two patients in the sham rTMS 
group were experiencing their first depressive episode; two 
patients in the active rTMS group and two patients in sham 
rTMS group suffered from recurrent depression (with several 
prior episodes); and three patients in active rTMS group and 
two patients in sham rTMS group were experiencing their 
first bipolar depressive episode. The demographic and clinical 
profiles of the two groups are shown in Table 1.
Clinical, neurocognitive, and social 
performance
Assessment of the effectiveness of blinding did not show results 
significantly different from what would be expected by chance. 
The rater guessed the assignment correctly in 54% of cases, 
whereas 60% of the patients guessed correctly when asked 
about which group they believed they had been assigned to. This 
result confirmed that the blinding procedure was efficient.
Table 2 shows the mean differences in scores between 
the groups at different weeks, regarding the measures of 
clinical, neuropsychological, and social performance. The 
active rTMS group but not the control group showed a posi-
tive response to treatment, with a reduction of at least 30% 
in HDRS/17 and EPDS scores at week 6 (after 2 weeks of 
follow-up).
Clinical psychiatric scales
In comparison with the sham group, the active rTMS group 
showed statistically significant differences in scores at base-
line versus week 6 for the HDRS/17 (P = 0.020), Global 
Assessment Scale (P = 0.037), and CGI1 (P = 0.047), when 
using the false discovery rate.
Although the active group showed a reduction of 39.4% 
in EPDS against 6.2% in the placebo group, this difference 
did not reach statistical significance. With respect to the 
HARS/14 (28.1% versus 6.6%), CGI3 (44.2% versus 26.3%), 
SF-36 for vitality (80.0% versus 17.9%) and mental health 
(102.3% versus 8.6%), no difference was observed for any 
interaction effects comparing the active and sham treatments 
when using the false discovery rate (Table 2), but statisti-
cally significant differences were observed using analysis of 
variance without false discovery rate correction; the values 
were HDRS/17 (P = 0.001), EDPS (P = 0.007), HARS/14 
(P = 0.012), Global Assessment Scale (P = 0.002; also in 
baseline versus week 4, P = 0.025), CGI1 (P = 0.004) and 
CGI3 (P = 0.038), and SF-36 for vitality (P = 0.054), and 
mental health (P = 0.054; Table 2 and Figure 1).
Neuropsychological battery
Between-group comparison associated with application of 
false discovery rate correction did not reveal statistically 
significant differences in performance for the Trail Making 
Test-B (31.4% versus 12.9%) or in the Victoria Stroop Test-
Interference (31.7% versus 10.0%). When using analysis of 
variance without false discovery rate correction, statistical 
differences appeared in both tests, ie, Trail Making Test-B 
(baseline versus week 4, P = 0.039) and Victoria Stroop 
Test-Interference (baseline versus week 6, P = 0.034, Table 2 
and Figure 1). No statistically significant differences were 
observed for the rest of the neuropsychological evaluation.
Social performance
Regarding the Social Adjustment Scale Self-Report, the groups 
differed at baseline in overall social performance (active 
rTMS 128.13 ± 14.09 versus sham rTMS 106.00 ± 15.77, 
P = 0.017). This scenario was reversed over the course of 
treatment. At week 6 (follow-up), the active rTMS group 
had improved general social performance scores by 25.5% 
(95.50 ± 32.00), whereas the sham group (102.00 ± 33.28) 
had a 3.8% improvement. This trend was not considered 
significant under false discovery rate control, although it 
was significant under the analysis of variance (P = 0.050). 
Additionally, in the Social Adjustment Scale Self-Report-
Work-at-Home, a statistically significant improvement was 
observed in both false discovery rate and analysis of variance 
analysis (baseline versus week 6, P = 0.020 and P = 0.001, 
respectively; and also in baseline versus week 4, P = 0.035; 
Table 2 and Figure 1).
Side effects
Subjects reported no significant side effects during the study. 
Two patients complained of minor scalp discomfort during 
application and/or mild headache immediately after their 
rTMS sessions.
Discussion
Extent to which rTMS enhances clinical, 
social, and cognitive functioning
In this study, stimulatory magnetic pulses (5 Hz) were 
delivered to the left dorsolateral prefrontal cortex in the active 
treatment group. Despite the fact that this area of the brain 
is involved in affective, social, and cognitive processes (due 
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Table 1 Demographic data, diagnostic/clinical data, and baseline rating scale scores for patients receiving repetitive transcranial 
magnetic stimulation (active or sham group)*
Characteristic Active rTMS  
n = 8
Sham rTMS 
n = 6
P-value
Age of the mother (years) 29.63 ± 6.37 26.67 ± 7.15 0.440a
Age of the infant (months) 4.13 ± 2.85 3.50 ± 2.74 0.507b
Maternal years of schooling 12.75 ± 2.55 11.50 ± 2.74 0.403a
Number of infant 1.50 ± 0.76 1.00 ± 0.00 0.105b
Socioeconomic class (ABIPEME)
 A or B, n (%) 3 (37.5) 2 (33.3) 0.334c
 C, n (%) 4 (50) 1 (16.7)
 D or E, n (%) 1 (12.5) 3 (50)
Marital status**
 Partner, n (%) 8 (100) 2 (33.3) 0.015c
 No partner, n (%) 0 (0) 4 (66.7)
Primiparity
 First infant, n (%) 5 (62.5) 6 (100) 0.472c
 Second infant, n (%) 2 (25.0) 0 (0)
 Third infant, n (%) 1 (12.5) 0 (0)
DSM-IV diagnosis (via the structured clinical interview)
 Major depressive disorder – onset in postpartum, n (%) 3 (37.5) 2 (33.3) 1,000c
 Major depressive disorder – recurrent episode, n (%) 2 (25) 2 (33.3)
 Affective bipolar disorder II – depressive episode in postpartum, n (%) 3 (37.5) 2 (33.3)
Onset of depressive symptoms
 Up to 5 days postpartum, n (%) 8 (100) 4 (66.7) 0.164c
 After 1 month postpartum, n (%) 0 (0) 1 (16.7)
 Between the 2nd and the 6th month after delivery, n (%) 0 (0) 1 (16.7)
Previous depressive episodes
 Yes, n (%) 5 (62.5) 3 (50) 1.000c
 No, n (%) 3 (37.5) 3 (50)
Previous hypomania episodes
 Yes, n (%) 1 (12.5) 2 (33.3) 0.538c
 No, n (%) 7 (87.5) 4 (66.7)
Previous psychopharmacological treatment
 Yes, n (%) 4 (50) 0 (0) 0.084c
 No, n (%) 4 (50) 6 (100)
Family history
 Yes, n (%) 6 (75) 4 (66.7) 1.000c
 No, n (%) 2 (25) 2 (33.3)
Medication in use: clonazepam (1 mg/day), n (%)
 Yes, n (%) 3 (37.5) 0 (0) 0.209c
 No, n (%) 5 (62.5) 6 (100)
Baseline rating scale scores
 hDRS/17 score 29.13 ± 5.64 26.67 ± 5.68 0.437a
 EPDS score 22.50 ± 3.16 21.50 ± 3.73 0.597a
 hARS/14 score 35.13 ± 8.39 32.83 ± 7.39 0.605a
 CG11 score 4.88 ± 0.35 4.67 ± 0.52 0.365b
 GAS score 38.88 ± 7.70 43.00 ± 7.29 0.331a
 SF-36-vitality score 28.13 ± 17.72 23.33 ± 16.02 0.605a
 SF36-mental health score 22.00 ± 13.86 23.33 ± 20.15 0.885a
Notes: at Student test; bWilcoxon–Mann–Whitney test; cFisher’s exact test; *data presented in terms of mean ± standard deviation (SD), unless otherwise specified; 
**statistically significant difference, Fisher’s exact test.
Abbreviations: rTMS, repetitive Transcranial Magnetic Stimulation; ABIPEME, Associação Brasileria de Institutos de Pesquisa de Mercado (Association of Marketing 
Research Firms in Brazil); DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; hDRS/17, 17-item hamilton Depression Rating Scale; EPDS, 
Edinburgh Postnatal Depression Scale; hARS/14, 14-item hamilton Anxiety Rating Scale; CGI, Clinical Global Impression – CGI1-Global Impression of Severity; GAS, Global 
Assessment Scale; SF-36, Medical Outcomes Study 36-item Short-form health Survey.
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to its highly connected structure), only marginal gains were 
observed in relation to social and cognitive dimensions.
There are several possible explanations for these findings, 
ie, that clinical dimensions tend to be more sensitive than 
cognitive and social performance to the effects of rTMS due 
to the spread of activation in frontolimbic networks, and that 
the clinical effects were stronger than the other two in this 
particular case because this dimension was the most affected 
at baseline. Adding to that, one could speculate that some 
results in this study became nonsignificant when switching 
from analysis of variance to Bonferroni testing, because this 
method increases the type II (false negative) error rate.44 
When we applied the false discovery rate, some significant 
results reappeared.
Skills essential for motherhood
rTMS did not produce any significant improvements in 
cognitive performance, although there were some nonsig-
nificant results pointing in this direction. It is worth noting 
that the observed moderate cognitive enhancement does not 
appear to reflect rehearsal, because both groups had the same 
opportunity to learn the tasks (this being a placebo-controlled 
study), whereas improvement was only observed in the active 
group. Considering that abilities such as memory, motor 
skills, mental flexibility, attention, and abstract learning are 
essential for parenting,45 we hypothesize that improvements 
in performance can enhance the capacity to cope with the 
challenges of the puerperium and exert a protective effect 
against pathological levels of stress for the mother and child, 
therefore inhibiting the chronification of depression.46
Cumulative effect of rTMS
We observed marginal cumulative effects of rTMS on 
affective, social, and cognitive dimensions from week 4 
to week 6. In this regard, the most promising results were 
found in relation to performance on the HDRS/17 and Social 
Adjustment Scale Self-Report-Work-at-Home (P = 0.020 
for both). This finding is interesting when considering that 
PPD is defined in light of very strong social bonds (reported 
by the family), which are not only dependent on the ability 
of the mother to be supportive in the affective domain, but 
also on her capacity to cope with practical issues related to 
family reorganization.
Limitations of this study
The main limitations of this study are that the sample size 
is not large and the marital status of the mothers was not 
standardized, with the inclusion of four women who had 
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no partner during the time this study was performed. These 
single mothers were randomized to the sham rTMS group. 
It is important to note that absence of a partner represents 
a risk factor for PPD, so that depression could be more 
remarkable in this group.5 However, this did not occur, 
as shown by equivalence in baseline performance on the 
HDRS/17 and EPDS between the groups. Another potential 
limitation relates to the fact that some patients suffered from 
recurrent depressive disorder. Finally, it was not possible to 
determine the extent to which the marginal cognitive and 
social improvements that were found represent byproducts 
of the clinical efficacy of the method.
Conclusion
This paper presents the results of the first double-blind, con-
trolled pilot trial on the effects of 5 Hz rTMS35 on clinical, 
social, and cognitive functioning in patients with PPD. At 
the same time as confirming improvement in affective and 
specific social domains, the study also provides preliminary 
evidence that rTMS produces small gains in overall social and 
specific cognitive performance. These social improvements 
may be strategic to the family in several ways, given that 
the puerperium involves decisive social demands associated 
with changes in family and household organization. Being 
unfit to cope with the practical demands of the puerperium 
can have deleterious effects that go beyond the initial period, 
affecting the child and perpetuating depression throughout 
generations, by both epigenetic and behaviorally mediated 
mechanisms.47,48
This study suggests that a paradigm shift in the treatment 
of PPD may be both desirable and feasible. rTMS produces 
results that are comparable with those of antidepressants, 
without the necessity to cease breastfeeding or transmit 
undesirable chemical compounds to the newborn. If cor-
roborated by clinical trials involving larger numbers of 
patients, this type of study may emerge as pioneering rTMS 
as a treatment of choice for PPD.
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